SCHEMBL31455685

SCHEMBL31455685

CC(C#N)c1cccc(C(=O)O)n1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.53
ALOX15 P16050 1/20 0.53
TSHR P16473 1/20 0.53
ACMSD Q8TDX5 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
LMNA P02545 3/20 0.44
ECE1 P42892 1/20 0.40
GNE Q9Y223 1/20 0.39
KMT2A Q03164 2/20 0.38
MGAM O43451 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
NAPRT Q6XQN6 1/20 0.36
P4HTM Q9NXG6 1/20 0.36
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
XDH P47989 1/20 0.35
PTGER1 P34995 1/20 0.35
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31455960 0.82 MAPT (0.44) KDM4ETSHRIRAK4L3MBTL1
SCHEMBL100967 0.82 KDM4E (0.61) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL16845797 0.80 KDM4E (0.59) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL19413764 0.79 KDM4E (0.57) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL14353836 0.79 KDM4E (0.57) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL17489063 0.79 KDM4E (0.57) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL12247340 0.76 KDM4E (0.53) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL11818115 0.76 KDM4E (0.53) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL26547511 0.76 KDM4E (0.53) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL22931517 0.76 KDM4E (0.64) KDM4EALOX15TSHRACMSDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025059562-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME ATAVISTIK BIO, INC. (US) 2025-03-20 WO disclosed